AHS

AHS 2025: CoQ10 shows promise in new daily persistent headache in children

June 25, 2025

Coenzyme Q10 (CoQ10) supplementation may play a role in new daily persistent headache (NDPH) resolution, according to findings presented at American Headache Society’s 2025 Annual Meeting.

This retrospective study from Children’s National Hospital examined treatment patterns in 182 pediatric patients diagnosed with NDPH, a chronic and often treatment-resistant condition. Average patient age was 15.5 years, and 78% were female. Headache resolution occurred in 25.8% of cases. Among various therapies analyzed, CoQ10 supplementation was the only intervention significantly associated with symptom resolution (17% in the resolved group vs. 4% in the non-resolved group; p = 0.010). Other treatments, including topiramate, magnesium, and onabotulinum toxin A, showed trends toward benefit but didn’t reach statistical significance. Regular exercise also trended toward improved outcomes (p = 0.058). The findings suggest a potential role for CoQ10 in managing pediatric NDPH and highlight the need for prospective trials to validate these associations and guide treatment strategies.

Source:

Takle, M et al. P-268: Coenzyme Q10 supplementation correlated with resolution of new daily persistent headache. Presented at American Headache Society 67th Annual Scientific Meeting. https://headachejournal.onlinelibrary.wiley.com/doi/full/10.1111/head.14957